Allergan and Humana Announce Research Partnership to Improve Health Outcomes

PRESS RELEASE

DUBLIN

and

LOUISVILLE, Ky.

,

Oct. 2, 2015

/PRNewswire/ --

Allergan plc

(NYSE: AGN), a leading global specialty pharmaceutical company, today announced a multi-year research collaboration with

Humana Inc.

(NYSE: HUM), one of the nation's leading health and well-being companies, to explore new ideas and ways to improve the health and well-being of patients, members and their caregivers.

A main objective of the

Allergan

and

Humana

collaboration is to study key issues and obtain a more comprehensive understanding of opportunities for improvement in care delivery.

"In today's changing health care environment, it is important for various stakeholders in the healthcare system to come together to gain in-depth understanding of unmet needs and find solutions to improve patient outcomes," said

Gavin Corcoran

, MD, FACP, Chief Medical Officer,

Allergan

. "This partnership aligns with our goal of leveraging real world data to build evidence and conduct comparative effectiveness research in collaboration with health care systems to better understand unmet needs, the natural history of disease, and interventions that improve both outcomes and the quality of care delivered to patients."

"The partnership with

Allergan

reflects

Humana's

commitment to improving health outcomes while reducing costs," said

William Fleming

, Pharm. D., President of Humana Pharmacy Solutions. "

Humana

is always looking to collaborate where we see an opportunity to make it easier for people to engage the health care system and looks forward to focusing on these initiatives with

Allergan

."

Under the terms of the agreement,

Allergan

and

Humana

will initially focus on the following initiatives:

• Variety of Diseases — Improving health of patients with central nervous system conditions, including Alzheimer's disease, as well as glaucoma and other eye diseases with opportunities to expand into other therapeutic areas as the collaboration progresses.
• Patient/Caregiver Relationship — Obtain a clearer picture of the attributes associated with caregiver burden from the caregiver perspective, and how self-reported caregiver burden relates to healthcare-related utilization and costs.
• Interventional Research — Conduct research based on interventional practices and predictive analytics, with a focus on treatment adherence, to ensure patients obtain the right medications at the right time.

One of the collaboration's first projects focuses on Alzheimer's patients' caregiver burden. Unlike caregiving for many terminal illnesses, caregiving for Alzheimer's disease may persist for much longer given that patients with Alzheimer's disease can live for many years.

"Caregivers are vulnerable to health consequences as a result of the chronic stressors associated with caring for a person with Alzheimer's disease," said

Roy Beveridge

, MD,

Humana's

Chief Medical Officer. "By working together,

Humana

and

Allergan

can help close a gap in care by going beyond the patient and focus on how to better understand and support caregivers."

Caregiver burden in Alzheimer's disease tends to increase with the progression of disease and corresponding increase in severity. In addition, caregiver traits themselves may also be influential; e.g., distance from patient, caregiver self-esteem, financial status, and health status may affect the level of caregiver burden.